Immunogenicity of hybrid hepatitis B surface antigen particles

Int Rev Immunol. 1994;11(2):143-51. doi: 10.3109/08830189409061722.

Abstract

Hepatitis B surface antigen (HBsAg) produced by recombinant DNA technology is now widely and safely used worldwide for hepatitis B vaccination. We used the HBsAg particle as a carrier molecule for presentation of selected human immunodeficiency virus type 1 (HIV-1) determinants to the immune system. Immunization studies carried out in primates showed that the particles elicit HIV specific virus neutralizing antibodies as well as T cell proliferative responses to both pathogens. As an experimental approach to active immunotherapy for hepatitis B virus (HBV) chronic carriers, we evaluated the efficiency of such hybrid antigen to overcome B cell tolerance in HBV transgenic mice.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / immunology*
  • Amino Acid Sequence
  • Animals
  • Blotting, Western
  • Genetic Vectors / immunology*
  • Hepatitis B Surface Antigens / immunology*
  • Hepatitis B Vaccines / immunology*
  • Molecular Sequence Data
  • Recombinant Fusion Proteins / immunology*
  • T-Lymphocytes / immunology
  • Vaccines, Synthetic / immunology

Substances

  • AIDS Vaccines
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Recombinant Fusion Proteins
  • Vaccines, Synthetic